Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

被引:45
|
作者
Vazquez, Iria [1 ]
Maicas, Miren [1 ,2 ]
Cervera, Jose [3 ]
Agirre, Xabier [1 ]
Marin-Bejar, Oskar [1 ]
Marcotegui, Nerea [1 ]
Vicente, Carmen [1 ]
Lahortiga, Idoya [4 ]
Gomez-Benito, Maria [1 ]
Carranza, Claudia [5 ]
Valencia, Ana [3 ]
Brunet, Salut [6 ]
Lumbreras, Eva [7 ,8 ]
Prosper, Felipe [1 ]
Gomez-Casares, Maria T. [9 ]
Hernandez-Rivas, Jesus M. [7 ,8 ]
Calasanz, Maria J. [2 ]
Sanz, Miguel A. [3 ]
Sierra, Jorge [6 ]
Odero, Maria D. [1 ,2 ]
机构
[1] Univ Navarra, CIMA, Div Oncol, Pamplona 31008, Spain
[2] Univ Navarra, Dept Genet, Pamplona 31008, Spain
[3] Univ Hosp La Fe, Valencia, Spain
[4] VIB, Dept Mol & Dev Genet, Human Genome Lab, Louvain, Belgium
[5] Inst Invest Genet, Milpas Altas, Guatemala
[6] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[7] Univ Salamanca, Hosp Univ Salamanca, E-37008 Salamanca, Spain
[8] Univ Salamanca, CSIC, E-37008 Salamanca, Spain
[9] Hosp Dr Negrin, Las Palmas Gran Canaria, Spain
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2011年 / 96卷 / 10期
关键词
AML; EVI1; overexpression; 3q; epigenetics; DE-NOVO AML; DNA METHYLATION; GENE-THERAPY; EXPRESSION; ONCOGENE; ACTIVATION; SURVIVAL; ABNORMALITIES; COMMON; FLT3;
D O I
10.3324/haematol.2011.040535
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The EVI1 gene (3q26) codes for a zinc finger transcription factor with important roles in both mammalian development and leukemogenesis. Over-expression of EVI1 through either 3q26 rearrangements, MLL fusions, or other unknown mechanisms confers a poor prognosis in acute myeloid leukemia. Design and Methods We analyzed the prevalence and prognostic impact of EVI1 over-expression in a series of 476 patients with acute myeloid leukemia, and investigated the epigenetic modifications of the EVI1 locus which could be involved in the transcriptional regulation of this gene. Results Our data provide further evidence that EVI1 over-expression is a poor prognostic marker in acute myeloid leukemia patients less than 65 years old. Moreover, we found that patients with no basal expression of EVI1 had a better prognosis than patients with expression/over-expression (P=0.036). We also showed that cell lines with over-expression of EVI1 had no DNA methylation in the promoter region of the EVI1 locus, and had marks of active histone modifications: H3 and H4 acetylation, and trimethylation of histone H3 lysine 4. Conversely, cell lines with no expression of EVI1 have DNA hypermethylation and are marked by repressive trimethylation of histone H3 lysine 27 at the EVI1 promoter. Conclusions Our results identify EVI1 over-expression as a poor prognostic marker in a large, independent cohort of acute myeloid leukemia patients less than 65 years old, and show that the total absence of EVI1 expression has a prognostic impact on the outcome of such patients. Furthermore, we demonstrated for the first time that an aberrant epigenetic pattern involving DNA methylation, H3 and H4 acetylation, and trimethylation of histone H3 lysine 4 and histone H3 lysine 27 might play a role in the transcriptional regulation of EVI1 in acute myeloid leukemia. This study opens new avenues for a better understanding of the regulation of EVI1 expression at a transcriptional level.
引用
收藏
页码:1448 / 1456
页数:9
相关论文
共 50 条
  • [31] The validation and clinical significance of LPCAT1 down-regulation in acute myeloid leukemia
    Chen, Qin
    Xu, Zijun
    Lin, Jiang
    Deng, Zhaoqun
    Qian, Jun
    Qian, Wei
    MOLECULAR BIOLOGY REPORTS, 2023, 50 (06) : 4955 - 4963
  • [32] The validation and clinical significance of LPCAT1 down-regulation in acute myeloid leukemia
    Qin Chen
    Zijun Xu
    Jiang Lin
    Zhaoqun Deng
    Jun Qian
    Wei Qian
    Molecular Biology Reports, 2023, 50 : 4955 - 4963
  • [33] Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable EVI1-CtBP1/2 Interaction and By Repressing Myeloid Regulator CEBPA
    Pastoors, Dorien
    Havermans, Marije
    Hoogenboezem, Remco
    Mulet-Lazaro, Roger
    Brian, Duncan
    Smeenk, Leonie
    Erpelinck-Verschueren, Claudia
    van Herk, Stanley
    Wouters, Bas
    Demmers, Jeroen A. A.
    Zuber, Johannes
    Enver, Tariq
    Groen, Richard W. J.
    Bindels, Eric
    Delwel, Ruud
    BLOOD, 2022, 140
  • [34] PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia
    Steinbach, Daniel
    Pfaffendorf, Nadine
    Wittig, Susan
    Gruhn, Bernd
    CANCER GENETICS AND CYTOGENETICS, 2007, 177 (01) : 51 - 54
  • [35] High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case
    D'Angio, Mariella
    Fazio, Grazia
    Grioni, Andrea
    Palamini, Sonia
    Sala, Simona
    Galbiati, Marta
    Biondi, Andrea
    Balduzzi, Adriana
    Rizzari, Carmelo
    Cazzaniga, Giovanni
    HEMASPHERE, 2020, 4 (05):
  • [36] Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia
    He, Pin-Fang
    Xu, Zi-Jun
    Zhou, Jing-Dong
    Li, Xi-Xi
    Zhang, Wei
    Wu, De-Hong
    Zhang, Zhi-Hui
    Lian, Xin-Yue
    Yao, Xin-Yu
    Deng, Zhao-Qun
    Lin, Jiang
    Qian, Jun
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (09) : 6604 - 6614
  • [37] EVI1 Disruption Post Neuroblastoma Treatment: A Case Analysis of Treatment-Associated Acute Myeloid Leukemia in a Pediatric Patient
    Zhang, Xin
    CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 893 - 899
  • [38] Prognosis and management of acute myeloid leukemia in patients with Down syndrome
    Caldwell, J. Timothy
    Ge, Yubin
    Taub, Jeffrey W.
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (06) : 831 - 840
  • [39] High EVI1 Expression Predicts Adverse Outcomes in Children With De Novo Acute Myeloid Leukemia
    Zheng, Yongzhi
    Huang, Yan
    Le, Shaohua
    Zheng, Hao
    Hua, Xueling
    Chen, Zaisheng
    Feng, Xiaoqin
    Li, Chunfu
    Zheng, Mincui
    Xu, Honggui
    He, Yingyi
    He, Xiangling
    Li, Jian
    Hu, Jianda
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [40] Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2
    Pastoors, Dorien
    Havermans, Marije
    Mulet-Lazaro, Roger
    Brian, Duncan
    Noort, Willy
    Grasel, Julius
    Hoogenboezem, Remco
    Smeenk, Leonie
    Demmers, Jeroen A. A.
    Milsom, Michael D.
    Enver, Tariq
    Groen, Richard W. J.
    Bindels, Eric
    Delwel, Ruud
    SCIENCE ADVANCES, 2024, 10 (20):